A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

        1 2 3 | Last   [Sort by number of followers]   [Restore default list]

  Subjects -> PHARMACY AND PHARMACOLOGY (Total: 575 journals)
Showing 1 - 200 of 253 Journals sorted alphabetically
AAPS Journal     Hybrid Journal   (Followers: 29)
AAPS Open     Open Access   (Followers: 5)
AAPS PharmSciTech     Hybrid Journal   (Followers: 6)
AboutOpen     Open Access  
ACS Pharmacology & Translational Science     Hybrid Journal   (Followers: 3)
Acta Pharmaceutica     Open Access   (Followers: 4)
Acta Pharmaceutica Indonesia     Open Access  
Acta Pharmaceutica Sinica B     Open Access   (Followers: 1)
Acta Pharmacologica Sinica     Hybrid Journal   (Followers: 2)
Acta Physiologica Hungarica     Full-text available via subscription  
Actualites Pharmaceutiques     Full-text available via subscription   (Followers: 4)
Advanced Drug Delivery Reviews     Hybrid Journal   (Followers: 95)
Advanced Herbal Medicine     Open Access   (Followers: 9)
Advanced Therapeutics     Hybrid Journal   (Followers: 1)
Advances in Medical, Pharmaceutical and Dental Research     Open Access   (Followers: 14)
Advances in Pharmacological and Pharmaceutical Sciences     Open Access   (Followers: 10)
Advances in Pharmacology     Full-text available via subscription   (Followers: 15)
Advances in Pharmacology and Pharmacy     Open Access   (Followers: 7)
Advances in Traditional Medicine     Hybrid Journal   (Followers: 5)
Adverse Drug Reaction Bulletin     Full-text available via subscription   (Followers: 4)
AJP : The Australian Journal of Pharmacy     Full-text available via subscription   (Followers: 11)
Al-Azhar Journal of Pharmaceutical Sciences     Open Access   (Followers: 5)
Alternatives to Laboratory Animals     Full-text available via subscription   (Followers: 7)
American Journal of Cardiovascular Drugs     Hybrid Journal   (Followers: 20)
American Journal of Drug Discovery and Development     Open Access   (Followers: 3)
American Journal of Health-System Pharmacy     Full-text available via subscription   (Followers: 52)
American Journal of Pharmacology and Toxicology     Open Access   (Followers: 21)
American Journal of Therapeutics     Hybrid Journal   (Followers: 11)
Analytical Methods     Hybrid Journal   (Followers: 7)
Annales Pharmaceutiques Francaises     Full-text available via subscription   (Followers: 1)
Annals of Pharmacotherapy     Hybrid Journal   (Followers: 53)
Annual Review of Pharmacology and Toxicology     Full-text available via subscription   (Followers: 27)
Anti-Infective Agents     Hybrid Journal   (Followers: 5)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry     Hybrid Journal   (Followers: 6)
Antibiotics     Open Access   (Followers: 12)
Antibody Therapeutics     Open Access  
Antiviral Chemistry and Chemotherapy     Open Access   (Followers: 1)
Antiviral Research     Hybrid Journal   (Followers: 8)
Archiv der Pharmazie     Hybrid Journal   (Followers: 3)
Archives of Drug Information     Hybrid Journal   (Followers: 4)
Archives of Pharmacal Research     Full-text available via subscription   (Followers: 1)
Archives of Pharmacy and Pharmaceutical Sciences     Open Access   (Followers: 2)
Archives of Razi Institute     Open Access   (Followers: 1)
Archivos Venezolanos de Farmacología y Terapéutica     Open Access  
Ars Pharmaceutica     Open Access  
Asian Journal of Medical and Pharmaceutical Researches     Open Access  
Asian Journal of Pharmaceutical Sciences     Open Access   (Followers: 1)
Asian Journal of Research in Medical and Pharmaceutical Sciences     Open Access  
ASSAY and Drug Development Technologies     Hybrid Journal   (Followers: 4)
Australian Journal of Herbal Medicine     Full-text available via subscription   (Followers: 5)
Australian Pharmacist     Full-text available via subscription   (Followers: 7)
Autonomic & Autacoid Pharmacology     Hybrid Journal  
Avicenna Journal of Phytomedicine     Open Access   (Followers: 1)
Bangladesh Journal of Pharmacology     Open Access  
Basic & Clinical Pharmacology & Toxicology     Hybrid Journal   (Followers: 11)
Behavioural Pharmacology     Hybrid Journal   (Followers: 2)
Biochemical Pharmacology     Hybrid Journal   (Followers: 9)
BioDrugs     Full-text available via subscription   (Followers: 4)
Biomaterials     Hybrid Journal   (Followers: 54)
Biomedical and Environmental Sciences     Full-text available via subscription   (Followers: 1)
Biomedicine & Pharmacotherapy     Full-text available via subscription   (Followers: 2)
Biometrical Journal     Hybrid Journal   (Followers: 6)
Biopharm International     Full-text available via subscription   (Followers: 8)
Biopharmaceutics and Drug Disposition     Hybrid Journal   (Followers: 12)
BMC Pharmacology     Open Access   (Followers: 3)
BMC Pharmacology & Toxicology     Open Access   (Followers: 5)
British Journal of Clinical Pharmacology     Hybrid Journal   (Followers: 25)
British Journal of Pharmacology     Hybrid Journal   (Followers: 14)
British Journal of Pharmacy (BJPharm)     Open Access   (Followers: 2)
Bulletin of Faculty of Pharmacy, Cairo University     Open Access   (Followers: 2)
CADTH Technology Overviews     Free  
Canadian Journal of Pain     Open Access   (Followers: 3)
Canadian Journal of Physiology and Pharmacology     Hybrid Journal   (Followers: 1)
Canadian Pharmacists Journal / Revue des Pharmaciens du Canada     Hybrid Journal   (Followers: 3)
Cancer Biotherapy & Radiopharmaceuticals     Hybrid Journal  
Cancer Chemotherapy and Pharmacology     Hybrid Journal   (Followers: 4)
Cardiovascular Drugs and Therapy     Hybrid Journal   (Followers: 12)
Cardiovascular Therapeutics     Open Access   (Followers: 3)
Cephalalgia Reports     Open Access  
Chemical Research in Toxicology     Hybrid Journal   (Followers: 20)
ChemMedChem     Hybrid Journal   (Followers: 9)
Chinese Herbal Medicines     Full-text available via subscription   (Followers: 1)
Chinese Journal of Pharmaceutical Analysis     Full-text available via subscription  
Clinical and Experimental Pharmacology and Physiology     Hybrid Journal   (Followers: 3)
Clinical and Translational Science     Open Access   (Followers: 4)
Clinical Complementary Medicine and Pharmacology     Open Access   (Followers: 1)
Clinical Drug Investigation     Full-text available via subscription   (Followers: 6)
Clinical Medicine Insights : Therapeutics     Open Access  
Clinical Neuropharmacology     Hybrid Journal   (Followers: 2)
Clinical Pharmacist     Partially Free   (Followers: 11)
Clinical Pharmacokinetics     Full-text available via subscription   (Followers: 16)
Clinical Pharmacology & Therapeutics     Hybrid Journal   (Followers: 31)
Clinical Pharmacology in Drug Development     Hybrid Journal   (Followers: 2)
Clinical Pharmacology: Advances and Applications     Open Access   (Followers: 5)
Clinical Research and Regulatory Affairs     Hybrid Journal   (Followers: 5)
Clinical Therapeutics     Hybrid Journal   (Followers: 10)
Clinical Toxicology     Hybrid Journal   (Followers: 18)
Clinical Trials     Hybrid Journal   (Followers: 12)
CNS Drug Reviews     Open Access   (Followers: 3)
CNS Drugs     Full-text available via subscription   (Followers: 10)
Combination Products in Therapy     Open Access  
Consultant Pharmacist     Full-text available via subscription   (Followers: 2)
Consumer Drugs     Full-text available via subscription  
Contract Pharma     Full-text available via subscription  
Cosmetics     Open Access   (Followers: 4)
CPT : Pharmacometrics & Systems Pharmacology     Open Access   (Followers: 6)
Critical Reviews in Clinical Laboratory Sciences     Hybrid Journal   (Followers: 16)
Critical Reviews in Toxicology     Hybrid Journal   (Followers: 22)
Current Bioactive Compounds     Hybrid Journal  
Current Cancer Therapy Reviews     Hybrid Journal   (Followers: 5)
Current Clinical Pharmacology     Hybrid Journal   (Followers: 3)
Current Drug Delivery     Hybrid Journal   (Followers: 6)
Current Drug Discovery Technologies     Hybrid Journal   (Followers: 5)
Current Drug Metabolism     Hybrid Journal   (Followers: 3)
Current Drug Safety     Hybrid Journal   (Followers: 8)
Current Drug Targets     Hybrid Journal   (Followers: 2)
Current Drug Therapy     Hybrid Journal   (Followers: 2)
Current Enzyme Inhibition     Hybrid Journal   (Followers: 2)
Current Issues in Pharmacy and Medical Sciences     Open Access   (Followers: 2)
Current Medical Science     Hybrid Journal  
Current Medicinal Chemistry     Hybrid Journal   (Followers: 7)
Current Molecular Pharmacology     Hybrid Journal  
Current Nanoscience     Hybrid Journal  
Current Neuropharmacology     Hybrid Journal   (Followers: 1)
Current Opinion in Pharmacology     Hybrid Journal   (Followers: 8)
Current Pharmaceutical Analysis     Hybrid Journal   (Followers: 1)
Current Pharmaceutical Biotechnology     Hybrid Journal   (Followers: 8)
Current Pharmaceutical Design     Hybrid Journal   (Followers: 4)
Current Pharmacogenomics and Personalized Medicine     Hybrid Journal   (Followers: 3)
Current Pharmacology Reports     Hybrid Journal  
Current Protocols in Pharmacology     Hybrid Journal  
Current Radiopharmaceuticals     Hybrid Journal   (Followers: 1)
Current Research in Drug Discovery     Open Access   (Followers: 1)
Current Research in Pharmacology and Drug Discovery     Open Access   (Followers: 5)
Current Therapeutic Research     Open Access   (Followers: 5)
Current trends in Biotechnology and Pharmacy     Open Access   (Followers: 7)
Current Vascular Pharmacology     Hybrid Journal   (Followers: 1)
Dhaka University Journal of Pharmaceutical Sciences     Open Access  
Die Pharmazie - An International Journal of Pharmaceutical Sciences     Full-text available via subscription   (Followers: 3)
Dose-Response     Open Access  
Drug and Chemical Toxicology     Hybrid Journal   (Followers: 12)
Drug and Therapeutics Bulletin     Hybrid Journal   (Followers: 8)
Drug Delivery     Open Access   (Followers: 7)
Drug Delivery and Translational Research     Hybrid Journal   (Followers: 2)
Drug Design, Development and Therapy     Open Access   (Followers: 1)
Drug Development and Industrial Pharmacy     Hybrid Journal   (Followers: 25)
Drug Development Research     Hybrid Journal   (Followers: 8)
Drug Discovery Today     Full-text available via subscription   (Followers: 64)
Drug Metabolism and Disposition     Hybrid Journal   (Followers: 9)
Drug Metabolism and Pharmacokinetics     Hybrid Journal   (Followers: 4)
Drug Metabolism Letters     Hybrid Journal   (Followers: 2)
Drug Metabolism Reviews     Hybrid Journal   (Followers: 3)
Drug Research     Hybrid Journal   (Followers: 1)
Drug Resistance Updates     Hybrid Journal   (Followers: 3)
Drug Safety     Full-text available via subscription   (Followers: 82)
Drug Safety - Case Reports     Open Access   (Followers: 2)
Drug Target Insights     Open Access  
Drug, Healthcare and Patient Safety     Open Access   (Followers: 8)
Drugs     Full-text available via subscription   (Followers: 182)
Drugs & Aging     Full-text available via subscription   (Followers: 9)
Drugs & Therapy Perspectives     Full-text available via subscription   (Followers: 9)
Drugs : Real World Outcomes     Hybrid Journal   (Followers: 1)
Drugs in R & D     Full-text available via subscription   (Followers: 2)
Drugs of the Future     Full-text available via subscription   (Followers: 4)
East and Central African Journal of Pharmaceutical Sciences     Open Access   (Followers: 1)
EJNMMI Radiopharmacy and Chemistry     Open Access  
EMC - Cosmetologia Medica e Medicina degli Inestetismi Cutanei     Full-text available via subscription  
Emerging Trends in Drugs, Addictions, and Health     Open Access   (Followers: 2)
Environmental Toxicology and Pharmacology     Hybrid Journal   (Followers: 7)
Epilepsy Research     Hybrid Journal   (Followers: 8)
Ethiopian Pharmaceutical Journal     Full-text available via subscription   (Followers: 1)
EUREKA : Health Sciences     Open Access  
European Journal of Clinical Pharmacology     Hybrid Journal   (Followers: 11)
European Journal of Drug Metabolism and Pharmacokinetics     Hybrid Journal   (Followers: 5)
European Journal of Hospital Pharmacy : Science and Practice (EJHP)     Hybrid Journal   (Followers: 5)
European Journal of Medicinal Plants     Open Access   (Followers: 4)
European Journal of Pharmaceutical Sciences     Hybrid Journal   (Followers: 84)
European Journal of Pharmaceutics and Biopharmaceutics     Hybrid Journal   (Followers: 23)
European Journal of Pharmacology     Hybrid Journal   (Followers: 3)
European Medical, Health and Pharmaceutical Journal     Open Access   (Followers: 2)
European Neuropsychopharmacology     Hybrid Journal   (Followers: 8)
European Pharmaceutical Journal     Open Access  
European Review for Medical and Pharmacological Sciences     Full-text available via subscription   (Followers: 1)
Experimental and Clinical Psychopharmacology     Full-text available via subscription   (Followers: 6)
Expert Opinion on Drug Delivery     Hybrid Journal   (Followers: 18)
Expert Opinion on Drug Discovery     Hybrid Journal   (Followers: 16)
Expert Opinion on Emerging Drugs     Hybrid Journal   (Followers: 7)
Expert Opinion on Investigational Drugs     Hybrid Journal   (Followers: 10)
Expert Opinion on Orphan Drugs     Hybrid Journal  
Expert Opinion on Pharmacotherapy     Hybrid Journal   (Followers: 7)
Expert Review of Anti-infective Therapy     Full-text available via subscription   (Followers: 5)
Expert Review of Cardiovascular Therapy     Full-text available via subscription   (Followers: 4)
Expert Review of Clinical Pharmacology     Hybrid Journal   (Followers: 2)
Expert Review of Molecular Diagnostics     Full-text available via subscription   (Followers: 5)
Expert Review of Pharmacoeconomics & Outcomes Research     Full-text available via subscription   (Followers: 6)
Expert Review of Precision Medicine and Drug Development     Hybrid Journal   (Followers: 4)
Exploratory Research in Clinical and Social Pharmacy     Open Access   (Followers: 4)
Fitoterapia     Hybrid Journal   (Followers: 5)
Food Additives & Contaminants Part A     Hybrid Journal   (Followers: 8)
Frontiers in Drug Design & Discovery     Hybrid Journal   (Followers: 7)

        1 2 3 | Last   [Sort by number of followers]   [Restore default list]

Similar Journals
Journal Cover
Drugs : Real World Outcomes
Number of Followers: 1  
 
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 2199-1154 - ISSN (Online) 2198-9788
Published by Springer-Verlag Homepage  [2468 journals]
  • Real-World Amount of Clotting Factor Products and Non-Factor Products
           Dispensed and Annual Medical Expenditures for Japanese Patients with
           Haemophilia A

    • Free pre-print version: Loading...

      Abstract: Background Treatment for haemophilia A has expanded from plasma-derived factor VIII (pdFVIII) and standard half-life (SHL) recombinant FVIII (rFVIII) to extended half-life (EHL) rFVIII and non-factor products that mimic FVIII activity. Objective To determine amounts of clotting factor concentrates (CFCs) and emicizumab dispensed and associated healthcare expenditures in Japanese patients with haemophilia A. Methods This retrospective, non-interventional, observational study analysed data from 2016 to 2020 from a large-scale, hospital-based administrative database. Patients had haemophilia A without inhibitors and ≥ 2 prescriptions of the same CFC or emicizumab. Results In total, 974 patients with haemophilia A (median age, 30.0 years; median follow-up, 3.7 years) were included. Outpatient use of EHL rFVIII and emicizumab increased, although pdFVIII/SHL rFVIII were still used over the study. Median annual total healthcare expenditures/patient increased from ¥9,200,230 in 2016 to ¥19,748,221 in 2020. Overall, the median annual drug expenditure/patient increased from ¥8,723,120 in 2016 to ¥18,051,689 in 2020. Drug expenditure was highest with emicizumab, with an increase in median annual expenditure/patient from 2018 (n = 4, ¥26,030,206) to 2020 (n = 107, ¥45,430,408). Overall, 233 patients (23.9%) switched from an SHL to an EHL product. Although amounts of FVIII prescribed increased in the 3 months after switching, overall, there was no noticeable difference before and after switching. Median total healthcare and FVIII product expenditures increased following switching. Conclusions Prescribing of EHL products increased over the study and healthcare expenditures increased for patients who switched from SHL to EHL rFVIII products.
      PubDate: 2024-08-10
      DOI: 10.1007/s40801-024-00420-7
       
  • Prescribing Cascades of Loop Diuretics and Anti-vertigo Drugs Following
           Treatment with Gabapentinoids and Benzodiazepines: Prescription Sequence
           Symmetry Analysis of a Large-Scale Claims Database Including Japanese
           Older Adults

    • Free pre-print version: Loading...

      Abstract: Background Gabapentinoids (GBP) and benzodiazepines (BZ) are commonly prescribed in older adults and their package inserts list edema and vertigo as adverse drug reactions. These adverse drug reactions may be treated with symptomatic drug therapies without discontinuing the culprit drugs or decreasing their dose, thereby initiating a prescribing cascade and often resulting in polypharmacy. Whether prescribing cascades occur in the treatment of edema and dizziness among Japanese patients treated with GBP and BZ has not been investigated, including treatment with mirogabalin, a class drug of GBP marketed in Japan. Objective We aimed to investigate prescribing cascades with GBP-induced and BZ-induced edema and dizziness treated with loop diuretics (LD) and anti-vertigo drugs (AVD), respectively, among older adults. Methods A prescription sequence symmetry analysis design was used to detect signals of prescribing cascades associated with edema and dizziness induced by GBP and BZ (exposure drugs). Loop diuretics and AVD were the outcome drugs used to identify prescribing cascades following the initiation of exposure drugs. The study population consisted of enrollees of a large-scale health claims database provided by DeSC Healthcare, Inc., between April 2014 and March 2021. Subjects eligible for a prescription sequence symmetry analysis were patients aged ≥ 65 years prescribed an outcome drug within 90 days before and after exposure drug initiation. A signal of a prescribing cascade was detected if secular trend-adjusted sequence ratios were statistically significant on comparison of the frequencies of outcome drug initiation before and after exposure drug initiation. Results We identified 2671 patients with prescriptions of a GBP-LD combination, 4009 with a GBP-AVD combination, 8675 with a BZ-LD combination, and 9462 with a BZ-AVD combination. The adjusted sequence ratios for GBP-LD and BZ-LD cascades were significantly larger than one (adjusted sequence ratio [95% confidence interval], 1.69 [1.56–1.83]; 1.35 [1.29–1.41], respectively), indicating positive signals of prescribing cascades. No signal was detected for the GBP-AVD or BZ-AVD cascade (0.89 [0.83–0.94]; 0.90 [0.87–0.94], respectively). The adjusted sequence ratio for the mirogabalin cascade was higher than that for pregabalin (2.23 [1.84–2.71] vs 1.59 [1.46–1.73]). Conclusions Our study provides good evidence that LD-prescribing cascades associated with edema would be a class effect of GBP and BZ. Edema emerging around 1 month after GBP initiation should be carefully differentiated from pathological edema, and undue LD prescription as a prescribing cascade should be avoided.
      PubDate: 2024-08-08
      DOI: 10.1007/s40801-024-00446-x
       
  • Enhancing Outcomes in Chronic Fibrotic Interstitial Lung Disease Through
           Aggressive Management of Nintedanib-Induced Adverse Drug Reactions: A
           Retrospective Analysis

    • Free pre-print version: Loading...

      Abstract: Background and Objectives Nintedanib, a tyrosine kinase inhibitor, is integral in slowing pulmonary fibrosis progression in chronic fibrotic interstitial lung disease (ILD). However, the occurrence of adverse drug reactions (ADRs) often limits its use, leading to treatment discontinuation, typically within 3–12 months. Discontinuation adversely affects patient outcomes. The study investigated whether aggressive ADR management can prolong nintedanib therapy and improve patient outcomes. Methods This retrospective, single-center study enrolled Taiwanese patients with chronic fibrotic ILD who were treated with nintedanib from January 2016 to December 2022 in Kaohsiung Chang Gung Memorial Hospital. Patients were categorized into those who discontinued treatment within 180 days and those continuing beyond. Management of ADRs was identified through concurrent prescriptions for symptoms such as nausea, vomiting, diarrhea, or hepatic dysfunction. Baseline demographics, comorbidities, pulmonary function tests, and instances of acute exacerbation were analyzed. Results The study enrolled 94 patients, with 71 (75.5%) experiencing ADRs. Among these, 41 (43.6%) discontinued nintedanib within 180 days. The administration of medications for managing nausea/vomiting [17 (41.5%) versus 36 (67.9%), p = 0.0103] and diarrhea [12 (29.3%) versus 33 (62.3%), p = 0.0015] was less frequent in the discontinued group compared with the continued group. Additionally, a higher incidence of acute exacerbation was observed in the discontinued group (34.1% versus 20.8%, p = 0.016). Conclusion Aggressive management of ADRs may enhance patient tolerance to nintedanib, potentially prolonging treatment duration and improving outcomes in chronic fibrotic ILD.
      PubDate: 2024-08-05
      DOI: 10.1007/s40801-024-00443-0
       
  • Exploring the Association Between Heart Rate Control and
           Rehospitalization: A Real-World Analysis of Patients Hospitalized with
           Heart Failure with Reduced Ejection Fraction

    • Free pre-print version: Loading...

      Abstract: Background In patients with heart failure with reduced ejection fraction (HFrEF), lower discharge heart rate (HR) is known to be associated with better outcomes. However, the effect of HR control on patient outcomes, and the demographic and clinical determinants of this association, are not well documented. Objectives The purpose of this work was to evaluate the association between the HR control and the risk of post-discharge rehospitalization in patients hospitalized with HFrEF. Methods Data were collected using a retrospective medical record review in the USA. Reduction in HR between admission and discharge (“HR control”) defined the primary exposure, categorized as no reduction, > 0 to < 20% reduction, and ≥ 20% reduction. Time to first rehospitalization in the post-discharge follow-up defined the study outcome and was analyzed using multivariable Cox regression modeling. Results A total of 1002 patients were analyzed (median age, 63 years; median follow-up duration, 24.2 months). At admission, 59.1% received beta-blockers, 57.4% received diuretics, and 47.5% received angiotensin-converting enzyme (ACE) inhibitors. Most patients (90.5%) achieved some HR control (38.4% achieved > 0 to < 20% reduction, and 52% achieved ≥ 20% reduction). Approximately 39% were rehospitalized during the follow-up (14% within 30 days). In multivariable analysis, patients with > 0 to < 20% reduction in HR had a 39% lower risk of rehospitalization [hazard ratio 0.61; 95% confidence interval (CI) 0.43–0.85]; patients with ≥ 20% reduction in HR had a 38% lower rehospitalization risk (hazard ratio 0.62; 95% CI 0.45–0.87) than those with no HR reduction. Conclusions Reduction in HR between admission and discharge was associated with reduced risk for rehospitalization. Findings indicate HR control as an important goal in the management of patients hospitalized for HFrEF.
      PubDate: 2024-08-01
      DOI: 10.1007/s40801-024-00436-z
       
  • Comparison of Real-World On-Label Treatment Persistence in Patients with
           Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor
           Necrosis Factor Inhibitors

    • Free pre-print version: Loading...

      Abstract: Background Treatment persistence among patients with psoriatic arthritis (PsA) is essential for achieving optimal treatment outcomes. Guselkumab, a fully human interleukin-23p19-subunit inhibitor, was approved by the United States (US) Food and Drug Administration for the treatment of active PsA in July 2020, with a dosing regimen of 100 mg at week 0, week 4, then every 8 weeks. In the Phase 3 DISCOVER-1 and DISCOVER-2 studies of patients with active PsA, 94% of guselkumab-randomized patients completed treatment through 1 year and 90% did so through 2 years (DISCOVER-2). Real-world evidence is needed to compare treatment persistence while following US prescribing guidelines (i.e., on-label persistence) for guselkumab versus subcutaneous (SC) tumor necrosis factor inhibitors (TNFis). Methods Adults with PsA receiving guselkumab or their first SC TNFi (i.e., adalimumab, certolizumab pegol, etanercept, or golimumab) between 14 July 2020 and 31 March 2022 were identified in the IQVIA PharMetrics® Plus database (first claim defined the treatment start date [index date]). Baseline characteristics and biologic use (biologic-naïve/biologic-experienced) were assessed during the 12-month period preceding the index date. Baseline characteristics were balanced between cohorts using propensity-score weighting based on the standardized mortality ratio approach. The follow-up period spanned from the index date until the earlier of the end of continuous insurance eligibility or end of data availability. On-label persistence, defined as the absence of treatment discontinuation (based on a gap of 112 days for guselkumab or 56 days for SC TNFi) or any dose escalation/reduction during follow-up, was assessed in the weighted treatment cohorts using Kaplan-Meier (KM) curves. A Cox proportional hazards model, further adjusted for baseline biologic use, was used to compare on-label persistence between the weighted cohorts. Results The guselkumab cohort included 526 patients (mean age 49.8 years; 61.2% female) and the SC TNFi cohort included 1953 patients (mean age: 48.5 years; 60.2% female). After weighting, baseline characteristics were well balanced with a mean follow-up of 12.3–12.4 months across cohorts; 51.5% of patients in the guselkumab cohort and 16.7% in the SC TNFi cohort received biologics in the 12-month baseline period. Respective rates of treatment persistence at 3, 6, 9, and 12 months were 91.2%, 84.1%, 75.9%, and 71.5% for the guselkumab cohort versus 77.3%, 61.6%, 50.0%, and 43.7% for the SC TNFi cohort (all log-rank p < 0.001). At 12 months, patients in the guselkumab cohort were 3.0 times more likely than patients in the SC TNFi cohort to remain persistent on treatment (p < 0.001). Median time to discontinuation was not reached for the guselkumab cohort and was 8.9 months for the SC TNFi cohort. Conclusion This real-world study employing US commercial health-plan claims data to assess on-label treatment persistence in PsA demonstrated that, at 12 months, guselkumab was associated with a 3 times greater likelihood of persistence compared with SC TNFi. Graphical abstract
      PubDate: 2024-07-31
      DOI: 10.1007/s40801-024-00428-z
       
  • Impact of Third-Generation Antiseizure Medications on People with Epilepsy
           in a Low-Income Population: The Brivaracetam Experience in a Real-World
           Study

    • Free pre-print version: Loading...

      Abstract: Background Third-generation antiseizure medications, such as brivaracetam, are recognized for their superior safety, tolerability, and pharmacokinetic profiles. However, their potential benefits are often limited in low-income populations because of challenges related to availability and affordability. Objective We aimed to evaluate the effectiveness and safety of brivaracetam for treating epilepsy in a low-income population, within a real-world setting. Methods This retrospective cohort study included individuals with epilepsy from a low-income population in Bogotá, Colombia, who were treated with brivaracetam between January 2020 and July 2023. Effectiveness (mean seizure reduction and ≥ 50% seizure reduction) and safety (retention rate and adverse events) were evaluated. Results A total of 106 individuals were included, with a median age of 33 years (interquartile range: 24–44). Most had focal epilepsy with a median disease duration of 25.4 years (standard deviation: 13.6). The baseline seizure frequency was 4 seizures per month (interquartile range: 2–15) and individuals had previously received a mean of 4.4 (standard deviation: 1.8) antiseizure medications. The mean percentage seizure reduction at 3, 6, and 12 months was 55.3%, 66.9%, and 63.8%, respectively. Additionally, 60%, 63.8%, and 65.9% of individuals achieved a ≥ 50% seizure reduction at 3, 6, and 12 months, respectively. Retention rate at 3 months was 89% (n = 95) and 18.7% (n = 20) reported adverse effects. Conclusions In a real-world setting, brivaracetam has been shown to be safe and effective for the treatment of epilepsy in individuals from a low-income population. This study suggests that people with epilepsy living in this context can significantly benefit from the use of third-generation antiseizure medications.
      PubDate: 2024-07-23
      DOI: 10.1007/s40801-024-00445-y
       
  • The Association Between Deep Vein Thrombosis, Pulmonary Embolism, and
           Janus Kinase Inhibitors: Reporting Status and Signal Detection in the
           Japanese Adverse Drug Event Report Database

    • Free pre-print version: Loading...

      Abstract: Background Although Janus kinase (JAK) inhibitors have expanding indications, deep vein thrombosis (DVT) and pulmonary embolism (PE) are serious adverse events associated with their use. Moreover, their analysis using the Japanese database of spontaneous adverse drug reaction reports has not yet been conducted. Objective The objective of this study was to analyze the Japanese Adverse Drug Event Report database (JADER) to evaluate the association between JAK inhibitors and DVT and PE. Methods JADER reports from April 2004 to October 2023 were analyzed. A classification of reports for the period covered was performed by drug, and an imbalance analysis was performed with oral JAK inhibitors as the target drug and DVT, PE, and “embolic and thrombotic events, venous” (Standardised MedDRA Query; SMQ) as the target adverse events. Reported odds ratios (ROR) and information components (IC) were calculated for signal detection. Results Overall, 6631 JAK inhibitor-related adverse events were reported, including 60 and 41 cases of DVT and PE, respectively. The ROR and IC of the JAK inhibitors for DVT were 2.52 (1.95–3.25) and 1.27 (0.41–2.13), while those of baricitinib for DVT were 4.37 (2.83–6.73) and 1.90 (0.47–3.33), respectively. ROR signals were detected for JAK inhibitors for PE and “embolic and thrombotic events, venous (SMQ),” overall and for several JAK inhibitors but none for IC. Conclusions Several JAK inhibitors are under postmarketing phase vigilance, and the number of reported adverse events is low. However, when administering these drugs, care should be taken to avoid the development of thromboembolism, considering the patient’s background.
      PubDate: 2024-07-20
      DOI: 10.1007/s40801-024-00447-w
       
  • Disease Stage and Motor Fluctuation Duration Predict Drug Tolerability: A
           Real-Life, Prospective Italian Multicenter Study on the Use of Opicapone
           in Parkinson’s Disease

    • Free pre-print version: Loading...

      Abstract: Background Opicapone is a third-generation catechol-O-methyl-transferase inhibitor currently used for the treatment of motor fluctuations in Parkinson’s disease. Its benefit and safety have been established by clinical trials; however, data about its use in a real-life context, and particularly in an Italian population of patients with Parkinson’s disease, are missing. Objectives We aimed to gather data about the real-life tolerability/safety of opicapone when used for the treatment of Parkinson’s disease-related motor fluctuations. Methods We enrolled 152 consecutive patients with Parkinson’s disease and followed them for 2 years after opicapone introduction. We obtained baseline clinical and demographical information, including disease duration, stage, phenotype, as well as axial and non-motor symptoms. We collected the reasons for any treatment interruption and adverse events emerging after opicapone introduction. Results Eighty-nine (58%) patients reported adverse events and 46 (30%) patients discontinued the treatment. Adverse events occurred less frequently in “earlier” patients accordingly to the disease course and l-Dopa treatment pathway; a motor fluctuation duration ≥12 months and Hoehn and Yahr scale score ≥2.5 were the main predictors of therapy withdrawal. Conclusions This study confirms the good tolerability/safety profile of opicapone in a real-life setting and provides country-specific data for Italian patients with Parkinson’s disease.
      PubDate: 2024-07-02
      DOI: 10.1007/s40801-024-00442-1
       
  • PCSK9 Inhibitors and Infection-Related Adverse Events: A Pharmacovigilance
           Study Using the World Health Organization VigiBase

    • Free pre-print version: Loading...

      Abstract: Aims Protein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are novel lipid-lowering agents used in patients with cardiovascular disease. Despite reassuring safety data from pivotal trials, increasing evidence from real-world studies suggests that PCSK9i increase the risk of bacterial and viral infections. Therefore, this study aimed to identify signals of infection-related adverse events (AEs) associated with PCSK9i. Methods We performed an observational pharmacovigilance study using the World Health Organization’s VigiBase, recorded up to December 2022. We included individual case safety reports (ICSRs) of PCSK9 inhibitors, alirocumab and evolocumab, and compared them with those of other drugs. Infection-related ICSRs were retrieved from the Medical Dictionary for Regulatory Activities System Organ Class ‘infections and infestations.’ Results Among 114,293 reports (258,099 drug–AE pairs) related to PCSK9 inhibitors, 54% included female patients, 41% included patients aged ≥65 years, and 82% included patients who received evolocumab. Additionally, beyond AEs recognized by regulatory authorities, organ infections such as influenza (reporting odds ratio [ROR] 2.89, 95% confidence interval [CI] 2.74–3.05), gastric infections (ROR 2.47, 95% CI 1.63–3.75), and kidney infections (ROR 1.36, 95% CI 1.06–1.73) were observed. Sensitivity analysis indicated a heightened risk of infection-related AEs associated with PCSK9i regardless of the specific drug type. Conclusions In addition to the labelled respiratory infections, six infection-related symptoms in the gastrointestinal, urinary, and renal organs were identified. Our findings support the need for systematic surveillance of infections among PCSK9i users.
      PubDate: 2024-07-02
      DOI: 10.1007/s40801-024-00430-5
       
  • Falls and Fractures among Nursing Home Residents Treated with Pimavanserin
           versus Other Atypical Antipsychotics: Analysis of Medicare Beneficiaries
           with Parkinson’s Disease Psychosis

    • Free pre-print version: Loading...

      Abstract: Background Reducing falls and fractures remains an important clinical goal in managing older residents with Parkinson’s disease psychosis (PDP) in long-term care/nursing home (LTC/NH) settings. Objectives This analysis examined risk of all-cause falls or fractures among PDP residents on continuous monotherapy with pimavanserin (PIM) versus (i) other atypical antipsychotics (AAPs) [quetiapine (QUE), risperidone (RIS), olanzapine (OLA), aripiprazole (ARI)] and (ii) QUE. Methods A retrospective analysis of parts A, B, and D claims from a 100% Medicare sample (2013–2019) in LTC/NH settings was conducted. LTC/NH residents in the USA initiating continuous monotherapy (PIM versus other AAPs; PIM versus QUE) for ≥ 6 months between 01 January 2014 and 31 December 2018 were 1:1 propensity score matched (PSM) on 31 variables (age, sex, race, region, and 27 Elixhauser comorbidities). Outcomes included three measures: risks of falls only, fractures only, and falls/fractures during 6-months follow-up. Demographic characteristics were described using chi-square and t-tests. Generalized linear models were used to assess difference in risks of falls/fractures. Results Of 7187 residents, 47.59% (n = 3420) were female and mean age was 78.8 (± 7.75) years. In total, 14% (n = 1005) were on PIM and 86% (n = 6182) were on other AAPs. After PSM, falls only among PIM residents (n = 1005) was 4.58% (n = 46) versus 7.66% (n = 77) for other AAPs (n = 1005) [relative risk (RR) = 0.63 (0.46, 0.86), p < 0.05] and 8.26% (n = 83) for QUE (n = 1005) residents (p < 0.05). Fractures only among PIM residents was 1.39% (n = 14) compared with 2.09% (n = 21) for other AAPs (p = 0.31) and 1.89% (n = 19) for QUE (p = 0.49), respectively. Taken together, falls/fractures among PIM residents were 5.67% (n = 57) versus 9.05% (n = 91) for other AAPs [RR = 0.63 (0.46, 0.86), p < 0.05] and 9.55% (n = 96) for QUE (p < 0.05), respectively. Conclusions In this analysis of LTC/NH residents with PDP, PIM had a 37% and 41% lower risk of all-cause falls/fractures versus other AAPs and versus QUE, respectively.
      PubDate: 2024-06-24
      DOI: 10.1007/s40801-024-00433-2
       
  • Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After
           Switching from IL-23 Inhibitors and Other Biologic Therapies: The
           CorEvitas Psoriasis Registry

    • Free pre-print version: Loading...

      Abstract: Background Prior work showed that patients from the CorEvitas Psoriasis Registry who had previously failed a prior biologic and then initiated ixekizumab demonstrated improvements in disease severity and patient-reported outcomes after 6 months. However, newer therapies such as interleukin-23 inhibitors (IL-23i) were not considered. Here, with more recent data including IL-23i, 6-month effectiveness of ixekizumab following a switch from any biologic was assessed as well as whether 6-month effectiveness of ixekizumab was impacted by prior biologic class. Methods We included CorEvitas Psoriasis Registry patients who initiated ixekizumab after discontinuing another biologic therapy and had a corresponding 6-month follow-up visit following ixekizumab initiation (N = 743, 2016–2023). Immediate prior biologic class was categorized as tumor necrosis factor inhibitor (TNFi) or interleukin-12/23 inhibitors (IL-12/23i, n = 405), non-ixekizumab interleukin-17i (IL-17i, n = 237), or IL-23i (n = 101). Adjusted mean changes in body surface area (BSA), Dermatology Life Quality Index (DLQI), itch, and skin pain were calculated for prior biologic class groups using analysis of covariance (ANCOVA). Proportions achieving ≥ 75%, ≥ 90%, and ≥ 100% improvement in Psoriasis Area and Severity Index (PASI75, PASI90, and PASI100, respectively), Investigator’s Global Assessment (IGA) 0/1, and DLQI 0/1 were calculated for all patients and compared among prior biologic classes via relative risks (RRs) and 95% confidence intervals (CIs) using multivariable modified Poisson regression. Results Mean improvements in BSA, DLQI, itch, and skin pain, were 7.6, 3.6, 23.3, and 16.7, respectively, for ixekizumab patients who switched from TNFi or IL-12/23i (all p < 0.05); 6.8, 3.3, 19.6, and 14.1, respectively, for those who switched from non-ixekizumab IL-17i (all p < 0.05); and 7.8, 3.4, 22.2, and 12.8, respectively, for those who switched from IL-23i (all p < 0.05). Overall, 54%, 41%, and 31% of ixekizumab initiators achieved PASI75, PASI90, and PASI100, respectively, 50% maintained or achieved IGA 0/1, and 48% maintained or achieved DLQI 0/1. The prior TNFi or IL-12/23i group was 31% more likely to achieve PASI100 (RR = 1.31, 95% CI 1.01, 1.69) and 32% more likely to maintain or achieve IGA 0/1 (RR = 1.32, 95% CI 1.11, 1.57), but not significantly more likely to achieve PASI90. The prior IL-23i group was 45% more likely to achieve PASI90 (RR = 1.45, 95% CI 1.10, 1.91), 55% more likely to achieve PASI100 (RR = 1.55, 95% CI 1.12, 2.13), and 39% more likely to maintain or achieve IGA 0/1 (RR = 1.39, 95% CI 1.12, 1.73) compared to the prior non-ixekizumab IL-17i group. Achievement of PASI75 and DLQI 0/1 was consistent across the prior TNFi or IL-12/23i, IL-23i, and non-ixekizumab IL-17i groups. Conclusions These updated findings with IL-23i data reaffirm that patients with psoriasis who switch to ixekizumab after discontinuing another biologic demonstrate improvement in disease severity and patient-reported outcomes at 6 months in real-world settings. Compared to patients who switched from another IL-17i, patients who switched class from a TNFi or IL-12/23i were more likely to achieve PASI100 and IGA 0/1, and patients who switched class from an IL-23i were more likely to achieve PASI90 in addition to PASI100 and IGA 0/1.
      PubDate: 2024-06-24
      DOI: 10.1007/s40801-024-00439-w
       
  • Omeprazole and Risk of Hypertension: Analysis of Existing Literature and
           the WHO Global Pharmacovigilance Database

    • Free pre-print version: Loading...

      Abstract: Introduction The association between omeprazole and hypertension is poorly documented. The summary of product characteristics of omeprazole approved by major regulators did not mention hypertension as an adverse drug event. Triggered by a locally reported case, this study was conducted to assess the possible causal relationship between omeprazole and hypertension. Methods Globally reported cases of hypertension following use of omeprazole submitted to the World Health Organization global database, VigiBase, were retrieved on 5 March 2024 and analyzed descriptively. Besides this, a literature search was made to identify preclinical, clinical, and epidemiological information on the association between omeprazole and hypertension or increased blood pressure using different data sources. Relevant information, gathered from different data sources, was finally systematically organized into an Austin Bradford-Hill causality assessment framework to assess the causal relationship between omeprazole and hypertension. Results VigiBase indicated a total of 1043 cases of hypertension related to omeprazole from 36 different countries. In the global database, a statistical signal was triggered (IC025: 0.12) on association of omeprazole and hypertension. From the 1043 cases, 65.0% and 10.6% were reported as ‘serious’ and ‘fatal’, respectively. Hypertension resolved following withdrawal of omeprazole in 85 cases and recurred after re-introduction of the suspect drug in 14 cases. In 225 cases, omeprazole was the only suspected drug, while in 122 cases, omeprazole was the sole drug administered. When only these 122 cases were considered, 29 cases had positive dechallenge, four cases were with positive rechallenge and the median time-to-onset was 2 days. Literature search identified a possible biological mechanism and some experimental evidence that indicates omeprazole could possibly cause hypertension. Conclusion Currently available totality of evidence suggests there is a possible causal relationship between omeprazole and hypertension. Hence, it is recommended to monitor and report any incidence of hypertension related to omeprazole, and further epidemiological studies are recommended to corroborate the suggested causal association.
      PubDate: 2024-06-22
      DOI: 10.1007/s40801-024-00441-2
       
  • Treatment Patterns and Clinical Outcomes Among Patients with Metastatic
           Non-small Cell Lung Cancer Without Actionable Genomic Alterations
           Previously Treated with Platinum-Based Chemotherapy and Immunotherapy

    • Free pre-print version: Loading...

      Abstract: Background For patients with metastatic non-small cell lung cancer, timely molecular testing is essential to determine the appropriate course of therapy. Initial treatment with platinum chemotherapy and/or an immune checkpoint inhibitor (ICI) is the standard of care for patients without actionable genomic alterations. Objective We aimed to assess treatment patterns and clinical outcomes among patients with metastatic non-small cell lung cancer, no actionable genomic alterations, and with prior ICI and platinum-based chemotherapy in a community oncology setting. Methods This retrospective observational study examined electronic health records from adult patients with an initial metastatic non-small cell lung cancer diagnosis without actionable genomic alterations from 2017 to 2019. Patients had received a subsequent line of therapy (LOT) [index] after discontinuing platinum-based chemotherapy plus an ICI in the previous one or two LOTs. Patient demographics and clinical characteristics were analyzed descriptively. Clinical outcomes were evaluated using Kaplan–Meier analyses. Results Among the study population (n = 961), the most common index LOT regimens were non-platinum-based chemotherapies (57.3%), platinum-based chemotherapies (12.9%), ICI-based chemotherapies (12.7%), platinum + ICI-based chemotherapies (9.4%), and other (7.7%). The most common post-index LOT regimens were non-platinum based (61.2%), ICI based (15.3%), platinum based (10.7%), platinum + ICI based (3.2%), and other (2.5%). Median time to treatment discontinuation, time to next treatment, and overall survival were numerically longest with index LOT ICI-based regimens (6.5, 9.9, and 18.9 months, respectively) and shortest with platinum-based regimens (2.8, 5.3, and 8.0 months, respectively) and non-platinum-based regimens (2.6, 5.0, and 7.8 months, respectively). Conclusions Among patients with metastatic non-small cell lung cancer without actionable genomic alterations previously treated with platinum + ICIs, non-platinum chemotherapy agents were most commonly prescribed in the index LOT. Clinical outcomes including time to treatment discontinuation, time to next treatment, and overall survival were short, highlighting the unmet need for more effective later-line treatments.
      PubDate: 2024-06-19
      DOI: 10.1007/s40801-024-00440-3
       
  • Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic
           HER2-Positive Breast Cancer: from Induction to Maintenance

    • Free pre-print version: Loading...

      Abstract: Background and Objective Dual human epidermal growth factor receptor 2 (HER2) blockade with trastuzumab and pertuzumab combined with taxane-based chemotherapy (Cht) has been the standard first-line treatment for HER2-positive metastatic breast cancer (mBC) for years, due to the impressive results of the CLEOPATRA study. Real-world (RW) studies have become critical for assessing treatment effectiveness and safety in real-life circumstances. The aim of this study was to analyze the treatment outcomes of first-line therapy for HER2-positive mBC in RW clinical practice, specifically focusing on the use of maintenance endocrine therapy (ET) in hormone receptor positive (HR-positive) patients. Methods This retrospective analysis included 106 HER2-positive mBC patients treated with trastuzumab and pertuzumab combined with taxane-based Cht from October 2015 to December 2020 at the University Hospital Centre Zagreb. Results At a median follow-up of 30 months, median progression-free survival (PFS) was 25 months for the total population (95% confidence interval [CI] 16 - not analyzed). Patients with de novo mBC had longer median PFS than patients with recurrent disease (not reached vs. 18 months; hazard ratio 1.99; 95% CI 0.69–3.64, p<0.022). Age, hormone receptor positivity, visceral involvement, number of Cht cycles and previous adjuvant trastuzumab did not impact PFS. Most HR-positive patients (N=55, 88.7%) received maintenance ET after induction Cht. Conclusion This retrospective study provides additional data on patient characteristics, treatment and outcomes of RW HER2-positive mBC patients treated with pertuzumab and trastuzumab as first-line therapy. In our institution, maintenance ET after induction Cht has become standard clinical practice.
      PubDate: 2024-06-16
      DOI: 10.1007/s40801-024-00438-x
       
  • The Clinical Course of Bowel Urgency Severity Among Patients with
           Inflammatory Bowel Disease—A Real-World Study

    • Free pre-print version: Loading...

      Abstract: Background Bowel urgency is a highly burdensome symptom among patients with inflammatory bowel disease (IBD). Objectives To assess changes in severity of bowel urgency and identify predictors of worsening or improvement among patients with Crohn’s disease (CD) and ulcerative colitis (UC) at 6 months from their enrollment visit. Methods Data from patients in the Study of a Prospective Adult Research Cohort with IBD were analyzed. Enrolled patients with CD or UC with 6-month visits were included. Changes and predictors of bowel urgency severity over 6 months in patients with CD or UC were examined using two separate analyses: (a) “worsening” versus “no change” excluding those with moderate-to-severe bowel urgency at enrollment, and (b) “improvement” versus “no change” excluding those with no bowel urgency at enrollment. The enrollment characteristics were compared within these groups. Results At baseline, in both CD and UC, use of biologics and/or immunomodulators at enrollment was similar across cohorts. Among patients with CD, 206 of 582 (35.4%) reported worsening, and 195 of 457 (42.7%) reported improvement in bowel urgency. Younger age (P = 0.013) and moderate-to-severe bowel urgency (P < 0.001) were associated with improvement. Moderate bowel urgency (P = 0.026) and bowel incontinence while awake (P = 0.022) were associated with worsening. Among patients with UC, 84 of 294 (28.6%) reported worsening, and 111 of 219 (50.7%) reported improvement in bowel urgency. Higher symptomatic disease severity (P = 0.011) and more severe bowel urgency (P < 0.001) were associated with improvement. Conclusions Bowel urgency is an unpredictable and unstable symptom among patients with IBD. Over 50% of patients with CD or UC experienced either worsening or improvement at 6 months postenrollment.
      PubDate: 2024-06-15
      DOI: 10.1007/s40801-024-00434-1
       
  • Incidence of Liver and Non-liver Cancers After Hepatitis C Virus
           Eradication: A Population-Based Cohort Study

    • Free pre-print version: Loading...

      Abstract: Background and Objectives Direct-acting antivirals (DAAs) offer a high rate of hepatitis C virus (HCV) eradication. However, concerns on the risk of cancer after HCV eradication remain. Our study aimed at quantifying the incidence of cancer in patients treated with anti-HCV therapies in Catalonia (Spain) and their matched controls. Methods This was a population-based study using real-world data from the public healthcare system of Catalonia between 2012 and 2016. Propensity score matching was performed in patients with HCV infection treated with interferon-based therapy (IFN), sequential IFN and DAA (IFN+DAA), and DAA only (DAA) with concurrent controls. We estimated the annual incidence of overall cancer, hepatocellular carcinoma, and non-liver cancer of HCV-treated patients and their corresponding rate ratios. Results The study included 11,656 HCV-treated patients and 49,545 controls. We found statistically significant increases in the rate of overall cancer for IFN+DAA-treated (rate ratio [RR] 1.77, 95% confidence interval [CI] 1.27–2.46) and DAA-treated patients (RR 1.90, 95% CI 1.66–2.19) and in the rate of HCC for IFN-treated (RR 1.50, 95% CI 1.02–2.22), IFN+DAA-treated (RR 3.89, 95% CI 2.26–6.69), and DAA-treated patients (RR 6.45, 95% CI 4.90–8.49) compared with their corresponding controls. Moreover, DAA-treated patients with cirrhosis showed an increased rate of overall cancer versus those without cirrhosis (RR 1.92, 95% CI 1.51–2.44). Conclusions Results showed that overall cancer and hepatocellular carcinoma incidence in Catalonia was significantly higher among HCV-treated patients compared with matched non-HCV-infected controls, and risks were higher in patients with cirrhosis. An increased awareness of the potential occurrence of uncommon malignant events and monitoring after HCV eradication therapy may benefit patients.
      PubDate: 2024-06-14
      DOI: 10.1007/s40801-024-00437-y
       
  • Association of Drug–Disease Interactions with Mortality or Readmission
           in Hospitalised Middle-Aged and Older Adults: A Systematic Review and
           Meta-Analysis

    • Free pre-print version: Loading...

      Abstract: Background and Objective Multimorbidity is common in hospitalised adults who are at increased risk of inappropriate prescribing including drug–disease interactions. These interactions occur when a medicine being used to treat one condition exacerbates a concurrent medical condition and may lead to adverse health outcomes. The aim of this review was to examine the association between drug–disease interactions and the risk of mortality and readmission in hospitalised middle-aged and older adults. Methods A systematic review was conducted on drug–disease interactions in hospitalised middle-aged (45–64 years) and older adults (≥65 years). The study protocol was prospectively registered with PROSPERO (Registration Number: CRD42022341998). Drug–disease interactions were defined as a medicine being used to treat one condition with the potential to exacerbate a concurrent medical condition or that were inappropriate based on a comorbid medical condition. Both observational and interventional studies were included. The outcomes of interest were mortality and readmissions. The databases searched included MEDLINE, CINAHL, EMBASE, Web of Science, SCOPUS and the Cochrane Library from inception to 12 July, 2022. A meta-analysis was performed to pool risk estimates using the random-effects model. Results A total of 563 studies were identified and four met the inclusion criteria. All were observational studies in older adults, with no studies identified in middle-aged adults. Most of the studies were at risk of bias because of an inadequate adjustment for covariates and a lack of clarity around individuals lost to follow-up. There were various definitions of drug–disease interactions within these four studies. Two studies assessed drugs that were contraindicated based on renal function, one assessed an individual drug–disease combination, and one was based on the clinical judgement of a pharmacist. There were two studies that showed an association between drug–disease interactions and the outcomes of interest. One reported that the use of diltiazem in patients with heart failure was associated with an increased risk of readmissions. The second reported that the use of medicines contraindicated according to renal function were associated with increased risk of all-cause mortality and a composite of mortality and readmission. Three of the studies (total study population = 5705) were amenable to a meta-analysis, which showed no significant association between drug–disease interactions and readmissions (odds ratio = 1.0, 95% confidence interval 0.80–1.38). Conclusions Few studies were identified examining the risk of drug–disease interactions and mortality and readmission in hospitalised adults. Most of the identified studies were at risk of bias. There is no universal accepted definition of drug–disease interactions in the literature. Further studies are needed to develop a standardised and accepted definition of these interactions to guide further research in this area.
      PubDate: 2024-06-09
      DOI: 10.1007/s40801-024-00432-3
       
  • Characterizing Utilization and Outcomes of Digoxin Immune Fab for Digoxin
           Toxicity

    • Free pre-print version: Loading...

      Abstract: Background Digoxin is a widely prescribed drug for congestive heart failure and atrial fibrillation. Digoxin has a narrow therapeutic index and toxicity can develop quite easily. Digoxin immune fab (DIF) is an effective treatment for toxicity, however there are limited studies characterizing its impact on clinical outcomes in real-world clinical practice. Objectives The aim of this study was to identify factors and healthcare outcomes associated with digoxin immune fab (DIF) treatment in patients with confirmed/suspected digoxin toxicity. Methods An IRB-approved retrospective chart review of digoxin toxic patients (2011–2020) presenting at an academic healthcare system was conducted. Demographic and clinical data were collected. Patients were stratified by DIF treatment versus non-DIF treatment. DIF utilization patterns (appropriate, use when not indicated, or underutilized) were determined using pre-defined criteria. Severe digoxin toxicity was defined as having one or more of the following: mental status disturbances, antiarrhythmic therapy, acute renal impairment or dehydration, serum digoxin concentration (SDC) > 4 ng/mL, or serum K+ > 5 mEq/mL. Logistic multivariable regression analysis evaluated factors associated with DIF use. All statistical analyses were performed in R version 4.1. Results Data from 96 patients (non-DIF treated group = 49; DIF treated group = 47) were analyzed. DIF was used appropriately in 70 patients (73%), underutilized in 19 (20%), and administered to 7 (7%) patients when it was not indicated. Several clinical parameters differentiated the DIF from the non-DIF group (p < 0.05) including higher mean SDC (3.41 ± 1.63 vs 2.87 ± 1.17), higher mean potassium (5.33 ± 1.48 vs 4.55 ± 0.87), more toxicity severity (85% vs 49%), and more likely to require cardiac pacing (26% vs 4%). Digoxin toxicity resolved sooner in the DIF group (coefficient − 0.702, 95% CI − 1.137 to − 0.267) (p < 0.01) and they had shorter intensive care unit lengths of stay (12.4 ± 20.3 vs 24.4 ± 28.7 days; p = 0.018). The all-cause mortality rate in patients appropriately managed with DIF therapy versus those patients where DIF was underutilized was 11% and 21%, respectively. Conclusions Based on our study population, DIF therapy appears to be beneficial in limiting duration of toxicity and intensive care unit lengths of stay in digoxin toxic patients. Although DIF was appropriately utilized in most cases, there was a relatively high proportion of cases in which DIF treatment was either underutilized or not indicated.
      PubDate: 2024-06-05
      DOI: 10.1007/s40801-024-00435-0
       
  • The Association Between Antidepressant Use and Drug-Induced Liver Injury:
           A Nationwide, Population-Based Case–Control Study in Taiwan

    • Free pre-print version: Loading...

      Abstract: Background and Objective The complex risk factors of liver injury have prevented the establishment of causal relationships. This study aimed to explore the effects of antidepressant class, cumulative days of medication exposure, presence of comorbidities, and the use of confounding drugs on the risk of antidepressant-induced liver injury. Methods The population-based case–control study sample included individuals registered on the Taiwan National Health Insurance Database between 2000 and 2018. Hospitalized patients with suspected drug-induced liver injury were considered as cases, while control subjects were matched 1:1 by age, gender, and index date (the first observed diagnosis of liver injury). Multivariable regression models were performed to evaluate the association between antidepressants and liver injury. Results The findings showed that antidepressant users exhibited a higher risk of liver injury (adjusted odds ratio [aOR] 1.16, 95% confidence interval [CI] 1.12–1.20), particularly those prescribed non-selective serotonin reuptake inhibitors (NSRIs; aOR 1.05; 95% CI 1.01–1.10), selective serotonin reuptake inhibitors (SSRIs; aOR 1.22; 95% CI 1.16–1.29), serotonin-norepinephrine reuptake inhibitors (SNRIs; aOR 1.18; 95% CI 1.13–1.24), and others (aOR 1.27; 95% CI 1.14–1.42). Moreover, cases exhibited a more significant proportion of antidepressant usage and longer durations of treatment compared with controls. The risk of liver injury was higher in the first 30 days of use across all classes of antidepressants (aOR 1.24; 95% CI 1.18–1.29). Conclusion SSRIs or SNRIs are commonly used to treat depression and other psychological disorders, and consideration of their potential effects on the liver is essential.
      PubDate: 2024-06-05
      DOI: 10.1007/s40801-024-00419-0
       
  • Correction to: Efficacy of Three Teriparatide Preparations and
           Romosozumab, Osteogenesis Promoters, in the Treatment of Fresh Vertebral
           Fractures: A Retrospective Observational Study

    • Free pre-print version: Loading...

      PubDate: 2024-04-06
      DOI: 10.1007/s40801-024-00421-6
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 18.97.14.85
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-
JournalTOCs
 
 

 A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

        1 2 3 | Last   [Sort by number of followers]   [Restore default list]

  Subjects -> PHARMACY AND PHARMACOLOGY (Total: 575 journals)
Showing 1 - 200 of 253 Journals sorted alphabetically
AAPS Journal     Hybrid Journal   (Followers: 29)
AAPS Open     Open Access   (Followers: 5)
AAPS PharmSciTech     Hybrid Journal   (Followers: 6)
AboutOpen     Open Access  
ACS Pharmacology & Translational Science     Hybrid Journal   (Followers: 3)
Acta Pharmaceutica     Open Access   (Followers: 4)
Acta Pharmaceutica Indonesia     Open Access  
Acta Pharmaceutica Sinica B     Open Access   (Followers: 1)
Acta Pharmacologica Sinica     Hybrid Journal   (Followers: 2)
Acta Physiologica Hungarica     Full-text available via subscription  
Actualites Pharmaceutiques     Full-text available via subscription   (Followers: 4)
Advanced Drug Delivery Reviews     Hybrid Journal   (Followers: 95)
Advanced Herbal Medicine     Open Access   (Followers: 9)
Advanced Therapeutics     Hybrid Journal   (Followers: 1)
Advances in Medical, Pharmaceutical and Dental Research     Open Access   (Followers: 14)
Advances in Pharmacological and Pharmaceutical Sciences     Open Access   (Followers: 10)
Advances in Pharmacology     Full-text available via subscription   (Followers: 15)
Advances in Pharmacology and Pharmacy     Open Access   (Followers: 7)
Advances in Traditional Medicine     Hybrid Journal   (Followers: 5)
Adverse Drug Reaction Bulletin     Full-text available via subscription   (Followers: 4)
AJP : The Australian Journal of Pharmacy     Full-text available via subscription   (Followers: 11)
Al-Azhar Journal of Pharmaceutical Sciences     Open Access   (Followers: 5)
Alternatives to Laboratory Animals     Full-text available via subscription   (Followers: 7)
American Journal of Cardiovascular Drugs     Hybrid Journal   (Followers: 20)
American Journal of Drug Discovery and Development     Open Access   (Followers: 3)
American Journal of Health-System Pharmacy     Full-text available via subscription   (Followers: 52)
American Journal of Pharmacology and Toxicology     Open Access   (Followers: 21)
American Journal of Therapeutics     Hybrid Journal   (Followers: 11)
Analytical Methods     Hybrid Journal   (Followers: 7)
Annales Pharmaceutiques Francaises     Full-text available via subscription   (Followers: 1)
Annals of Pharmacotherapy     Hybrid Journal   (Followers: 53)
Annual Review of Pharmacology and Toxicology     Full-text available via subscription   (Followers: 27)
Anti-Infective Agents     Hybrid Journal   (Followers: 5)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry     Hybrid Journal   (Followers: 6)
Antibiotics     Open Access   (Followers: 12)
Antibody Therapeutics     Open Access  
Antiviral Chemistry and Chemotherapy     Open Access   (Followers: 1)
Antiviral Research     Hybrid Journal   (Followers: 8)
Archiv der Pharmazie     Hybrid Journal   (Followers: 3)
Archives of Drug Information     Hybrid Journal   (Followers: 4)
Archives of Pharmacal Research     Full-text available via subscription   (Followers: 1)
Archives of Pharmacy and Pharmaceutical Sciences     Open Access   (Followers: 2)
Archives of Razi Institute     Open Access   (Followers: 1)
Archivos Venezolanos de Farmacología y Terapéutica     Open Access  
Ars Pharmaceutica     Open Access  
Asian Journal of Medical and Pharmaceutical Researches     Open Access  
Asian Journal of Pharmaceutical Sciences     Open Access   (Followers: 1)
Asian Journal of Research in Medical and Pharmaceutical Sciences     Open Access  
ASSAY and Drug Development Technologies     Hybrid Journal   (Followers: 4)
Australian Journal of Herbal Medicine     Full-text available via subscription   (Followers: 5)
Australian Pharmacist     Full-text available via subscription   (Followers: 7)
Autonomic & Autacoid Pharmacology     Hybrid Journal  
Avicenna Journal of Phytomedicine     Open Access   (Followers: 1)
Bangladesh Journal of Pharmacology     Open Access  
Basic & Clinical Pharmacology & Toxicology     Hybrid Journal   (Followers: 11)
Behavioural Pharmacology     Hybrid Journal   (Followers: 2)
Biochemical Pharmacology     Hybrid Journal   (Followers: 9)
BioDrugs     Full-text available via subscription   (Followers: 4)
Biomaterials     Hybrid Journal   (Followers: 54)
Biomedical and Environmental Sciences     Full-text available via subscription   (Followers: 1)
Biomedicine & Pharmacotherapy     Full-text available via subscription   (Followers: 2)
Biometrical Journal     Hybrid Journal   (Followers: 6)
Biopharm International     Full-text available via subscription   (Followers: 8)
Biopharmaceutics and Drug Disposition     Hybrid Journal   (Followers: 12)
BMC Pharmacology     Open Access   (Followers: 3)
BMC Pharmacology & Toxicology     Open Access   (Followers: 5)
British Journal of Clinical Pharmacology     Hybrid Journal   (Followers: 25)
British Journal of Pharmacology     Hybrid Journal   (Followers: 14)
British Journal of Pharmacy (BJPharm)     Open Access   (Followers: 2)
Bulletin of Faculty of Pharmacy, Cairo University     Open Access   (Followers: 2)
CADTH Technology Overviews     Free  
Canadian Journal of Pain     Open Access   (Followers: 3)
Canadian Journal of Physiology and Pharmacology     Hybrid Journal   (Followers: 1)
Canadian Pharmacists Journal / Revue des Pharmaciens du Canada     Hybrid Journal   (Followers: 3)
Cancer Biotherapy & Radiopharmaceuticals     Hybrid Journal  
Cancer Chemotherapy and Pharmacology     Hybrid Journal   (Followers: 4)
Cardiovascular Drugs and Therapy     Hybrid Journal   (Followers: 12)
Cardiovascular Therapeutics     Open Access   (Followers: 3)
Cephalalgia Reports     Open Access  
Chemical Research in Toxicology     Hybrid Journal   (Followers: 20)
ChemMedChem     Hybrid Journal   (Followers: 9)
Chinese Herbal Medicines     Full-text available via subscription   (Followers: 1)
Chinese Journal of Pharmaceutical Analysis     Full-text available via subscription  
Clinical and Experimental Pharmacology and Physiology     Hybrid Journal   (Followers: 3)
Clinical and Translational Science     Open Access   (Followers: 4)
Clinical Complementary Medicine and Pharmacology     Open Access   (Followers: 1)
Clinical Drug Investigation     Full-text available via subscription   (Followers: 6)
Clinical Medicine Insights : Therapeutics     Open Access  
Clinical Neuropharmacology     Hybrid Journal   (Followers: 2)
Clinical Pharmacist     Partially Free   (Followers: 11)
Clinical Pharmacokinetics     Full-text available via subscription   (Followers: 16)
Clinical Pharmacology & Therapeutics     Hybrid Journal   (Followers: 31)
Clinical Pharmacology in Drug Development     Hybrid Journal   (Followers: 2)
Clinical Pharmacology: Advances and Applications     Open Access   (Followers: 5)
Clinical Research and Regulatory Affairs     Hybrid Journal   (Followers: 5)
Clinical Therapeutics     Hybrid Journal   (Followers: 10)
Clinical Toxicology     Hybrid Journal   (Followers: 18)
Clinical Trials     Hybrid Journal   (Followers: 12)
CNS Drug Reviews     Open Access   (Followers: 3)
CNS Drugs     Full-text available via subscription   (Followers: 10)
Combination Products in Therapy     Open Access  
Consultant Pharmacist     Full-text available via subscription   (Followers: 2)
Consumer Drugs     Full-text available via subscription  
Contract Pharma     Full-text available via subscription  
Cosmetics     Open Access   (Followers: 4)
CPT : Pharmacometrics & Systems Pharmacology     Open Access   (Followers: 6)
Critical Reviews in Clinical Laboratory Sciences     Hybrid Journal   (Followers: 16)
Critical Reviews in Toxicology     Hybrid Journal   (Followers: 22)
Current Bioactive Compounds     Hybrid Journal  
Current Cancer Therapy Reviews     Hybrid Journal   (Followers: 5)
Current Clinical Pharmacology     Hybrid Journal   (Followers: 3)
Current Drug Delivery     Hybrid Journal   (Followers: 6)
Current Drug Discovery Technologies     Hybrid Journal   (Followers: 5)
Current Drug Metabolism     Hybrid Journal   (Followers: 3)
Current Drug Safety     Hybrid Journal   (Followers: 8)
Current Drug Targets     Hybrid Journal   (Followers: 2)
Current Drug Therapy     Hybrid Journal   (Followers: 2)
Current Enzyme Inhibition     Hybrid Journal   (Followers: 2)
Current Issues in Pharmacy and Medical Sciences     Open Access   (Followers: 2)
Current Medical Science     Hybrid Journal  
Current Medicinal Chemistry     Hybrid Journal   (Followers: 7)
Current Molecular Pharmacology     Hybrid Journal  
Current Nanoscience     Hybrid Journal  
Current Neuropharmacology     Hybrid Journal   (Followers: 1)
Current Opinion in Pharmacology     Hybrid Journal   (Followers: 8)
Current Pharmaceutical Analysis     Hybrid Journal   (Followers: 1)
Current Pharmaceutical Biotechnology     Hybrid Journal   (Followers: 8)
Current Pharmaceutical Design     Hybrid Journal   (Followers: 4)
Current Pharmacogenomics and Personalized Medicine     Hybrid Journal   (Followers: 3)
Current Pharmacology Reports     Hybrid Journal  
Current Protocols in Pharmacology     Hybrid Journal  
Current Radiopharmaceuticals     Hybrid Journal   (Followers: 1)
Current Research in Drug Discovery     Open Access   (Followers: 1)
Current Research in Pharmacology and Drug Discovery     Open Access   (Followers: 5)
Current Therapeutic Research     Open Access   (Followers: 5)
Current trends in Biotechnology and Pharmacy     Open Access   (Followers: 7)
Current Vascular Pharmacology     Hybrid Journal   (Followers: 1)
Dhaka University Journal of Pharmaceutical Sciences     Open Access  
Die Pharmazie - An International Journal of Pharmaceutical Sciences     Full-text available via subscription   (Followers: 3)
Dose-Response     Open Access  
Drug and Chemical Toxicology     Hybrid Journal   (Followers: 12)
Drug and Therapeutics Bulletin     Hybrid Journal   (Followers: 8)
Drug Delivery     Open Access   (Followers: 7)
Drug Delivery and Translational Research     Hybrid Journal   (Followers: 2)
Drug Design, Development and Therapy     Open Access   (Followers: 1)
Drug Development and Industrial Pharmacy     Hybrid Journal   (Followers: 25)
Drug Development Research     Hybrid Journal   (Followers: 8)
Drug Discovery Today     Full-text available via subscription   (Followers: 64)
Drug Metabolism and Disposition     Hybrid Journal   (Followers: 9)
Drug Metabolism and Pharmacokinetics     Hybrid Journal   (Followers: 4)
Drug Metabolism Letters     Hybrid Journal   (Followers: 2)
Drug Metabolism Reviews     Hybrid Journal   (Followers: 3)
Drug Research     Hybrid Journal   (Followers: 1)
Drug Resistance Updates     Hybrid Journal   (Followers: 3)
Drug Safety     Full-text available via subscription   (Followers: 82)
Drug Safety - Case Reports     Open Access   (Followers: 2)
Drug Target Insights     Open Access  
Drug, Healthcare and Patient Safety     Open Access   (Followers: 8)
Drugs     Full-text available via subscription   (Followers: 182)
Drugs & Aging     Full-text available via subscription   (Followers: 9)
Drugs & Therapy Perspectives     Full-text available via subscription   (Followers: 9)
Drugs : Real World Outcomes     Hybrid Journal   (Followers: 1)
Drugs in R & D     Full-text available via subscription   (Followers: 2)
Drugs of the Future     Full-text available via subscription   (Followers: 4)
East and Central African Journal of Pharmaceutical Sciences     Open Access   (Followers: 1)
EJNMMI Radiopharmacy and Chemistry     Open Access  
EMC - Cosmetologia Medica e Medicina degli Inestetismi Cutanei     Full-text available via subscription  
Emerging Trends in Drugs, Addictions, and Health     Open Access   (Followers: 2)
Environmental Toxicology and Pharmacology     Hybrid Journal   (Followers: 7)
Epilepsy Research     Hybrid Journal   (Followers: 8)
Ethiopian Pharmaceutical Journal     Full-text available via subscription   (Followers: 1)
EUREKA : Health Sciences     Open Access  
European Journal of Clinical Pharmacology     Hybrid Journal   (Followers: 11)
European Journal of Drug Metabolism and Pharmacokinetics     Hybrid Journal   (Followers: 5)
European Journal of Hospital Pharmacy : Science and Practice (EJHP)     Hybrid Journal   (Followers: 5)
European Journal of Medicinal Plants     Open Access   (Followers: 4)
European Journal of Pharmaceutical Sciences     Hybrid Journal   (Followers: 84)
European Journal of Pharmaceutics and Biopharmaceutics     Hybrid Journal   (Followers: 23)
European Journal of Pharmacology     Hybrid Journal   (Followers: 3)
European Medical, Health and Pharmaceutical Journal     Open Access   (Followers: 2)
European Neuropsychopharmacology     Hybrid Journal   (Followers: 8)
European Pharmaceutical Journal     Open Access  
European Review for Medical and Pharmacological Sciences     Full-text available via subscription   (Followers: 1)
Experimental and Clinical Psychopharmacology     Full-text available via subscription   (Followers: 6)
Expert Opinion on Drug Delivery     Hybrid Journal   (Followers: 18)
Expert Opinion on Drug Discovery     Hybrid Journal   (Followers: 16)
Expert Opinion on Emerging Drugs     Hybrid Journal   (Followers: 7)
Expert Opinion on Investigational Drugs     Hybrid Journal   (Followers: 10)
Expert Opinion on Orphan Drugs     Hybrid Journal  
Expert Opinion on Pharmacotherapy     Hybrid Journal   (Followers: 7)
Expert Review of Anti-infective Therapy     Full-text available via subscription   (Followers: 5)
Expert Review of Cardiovascular Therapy     Full-text available via subscription   (Followers: 4)
Expert Review of Clinical Pharmacology     Hybrid Journal   (Followers: 2)
Expert Review of Molecular Diagnostics     Full-text available via subscription   (Followers: 5)
Expert Review of Pharmacoeconomics & Outcomes Research     Full-text available via subscription   (Followers: 6)
Expert Review of Precision Medicine and Drug Development     Hybrid Journal   (Followers: 4)
Exploratory Research in Clinical and Social Pharmacy     Open Access   (Followers: 4)
Fitoterapia     Hybrid Journal   (Followers: 5)
Food Additives & Contaminants Part A     Hybrid Journal   (Followers: 8)
Frontiers in Drug Design & Discovery     Hybrid Journal   (Followers: 7)

        1 2 3 | Last   [Sort by number of followers]   [Restore default list]

Similar Journals
Similar Journals
HOME > Browse the 73 Subjects covered by JournalTOCs  
SubjectTotal Journals
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 18.97.14.85
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-